Drug Discovery World
DECEMBER 7, 2023
A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. NMRA-266, an allosteric modulator that works through a mechanism that has been clinically validated in the treatment of disorders like schizophrenia, will be developed by Neumora Therapeutics.
BioPharma Drive: Drug Pricing
DECEMBER 8, 2023
In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Conversations in Drug Development Trends
DECEMBER 7, 2023
Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. As a result, various CROs have undergone significant consolidations and acquisitions of specialized capabilities to address the escalating complexity in clinical trials.
National Drug & Alcohol Research Centre Blog
DECEMBER 4, 2023
Kendal Chidwick NDARC’s Kendal Chidwick discusses the findings from a recently published study that examined how patterns of opioid agonist treatment medicines have changed over the past decade. In Australia, both methadone and buprenorphine have been subsidised by the Pharmaceutical Benefit Scheme (PBS) for the treatment of opioid dependence (termed ‘opioid agonist treatment’ or OAT) for several decades.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Discovery World
DECEMBER 5, 2023
Cancer Research UK (CRUK), Cancer Research Horizons, and precision oncology company Guardant Health have launched a collaboration to advance cancer treatment. The agreement will enable the parties to discuss opportunities for collaboration to support the charity’s research and clinical development activities, focusing primarily on its clinical trials run by its Centre for Drug Development.
keypoint
DECEMBER 4, 2023
Keystone Symposia is pleased to introduce the Keystone Symposia Fellows Class of 2024! This year we welcome seven early-career investigators and seven post-doctoral fellows, a new addition to the program this year.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
BioPharma Drive: Drug Pricing
DECEMBER 6, 2023
The deal hands AbbVie a portfolio of psychiatric medicines that originated within Pfizer, among them a closely watched schizophrenia treatment that’s in late-stage testing.
Drug Discovery World
DECEMBER 6, 2023
Osteoarthritis may be treatable and reversible, according to a new University of Adelaide study. The researchers have discovered a novel population of stem cells – marked by the Gremlin 1 gene – responsible for the progression of osteoarthritis. Treatment with fibroblast growth factor 18 (FGF18) stimulated the proliferation of Gremlin 1 cells in joint cartilage in mice, leading to significant recovery of cartilage thickness and reduced osteoarthritis.
Science Daily: Pharmacology News
DECEMBER 4, 2023
What wiped out the dinosaurs? A meteorite plummeting to Earth is only part of the story, a new study suggests. Climate change triggered by massive volcanic eruptions may have ultimately set the stage for the dinosaur extinction, challenging the traditional narrative that a meteorite alone delivered the final blow to the ancient giants.
Drugs.com
DECEMBER 8, 2023
FRIDAY, Dec. 8, 2023 -- The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first treatment ever approved that uses gene-editing technology. Casgevy, developed by Vertex.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
BioPharma Drive: Drug Pricing
DECEMBER 7, 2023
The funding is indicative of investor interest in an area of drug research that involves at least a dozen startups and multiple publicly traded companies.
Drug Discovery World
DECEMBER 8, 2023
Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The once-fictional artificial intelligence (AI) depicted in literature and movies has transitioned into a tangible and easily accessible tool in our modern world. General AI tools such as ChatGPT have acted as a catalyst, igniting a wave of AI innovation akin to the early days of the internet era.
Science Daily: Pharmacology News
DECEMBER 6, 2023
Scientists have identified abnormal aggregates of a protein called TAF15 in the brains of individuals with early-onset dementia, known as frontotemporal dementia, where the cause was not previously known.
Drugs.com
DECEMBER 8, 2023
FRIDAY, Dec. 8, 2023 -- Could blockbuster diabetes and weight-loss meds such as Ozempic, Wegovy, Mounjaro and Zepbound also lower users' odds for colon cancer? New research suggests they might.All of these medications (and more) fall into a class.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Antidote
DECEMBER 7, 2023
Chronic spontaneous urticaria, also called chronic idiopathic urticaria, is a type of chronic hives that come and go unexpectedly. These hives persist daily for a minimum of six weeks without a clear cause or trigger. While this condition can affect anyone at any point, women experience it twice as often as men , and it’s most common between the ages of 20 and 40.
Drug Discovery World
DECEMBER 8, 2023
Scientists have identified abnormal aggregates of a protein called TAF15 in the brains of individuals with early-onset dementia, known as frontotemporal dementia, where the cause was not previously known. The research led by scientists from the Medical Research Council (MRC) Laboratory of Molecular Biology, in Cambridge, UK, could provide a target for the future development of diagnostic tests and treatments.
Science Daily: Pharmacology News
DECEMBER 4, 2023
Decreasing pancreatic beta cell numbers -- the only cells that produce insulin -- is a leading cause of diabetes. In a promising development, a research group has revealed that stimulating autonomic vagal nerves connected to the pancreas can improve the function and also increase the number of pancreatic beta cells in mice.
Drugs.com
DECEMBER 4, 2023
MONDAY, Dec. 4, 2023 -- As syphilis cases surge across America, a group representing the nation's STD specialists says members are reporting shortages of a drug essential to fighting the disease. In a survey from the National Coalition of STD.
BioPharma Drive: Drug Pricing
DECEMBER 8, 2023
Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2 million, while a competing genetic medicine also cleared Friday is priced at $3.1 million.
Drug Discovery World
DECEMBER 7, 2023
Inipharm has initiated Phase I dosing of its lead candidate, INI-822, which is a small-molecule inhibitor for HSD17B13, a gene implicated in nonalcoholic steatohepatitis (NASH). Loss-of-function variants of HSD17B13 are known to be associated with reduced incidence risk and severity of multiple liver diseases. CN Bio’s PhysioMimix Organ-on-a-Chip (OOC) Systems and NASH ‘in-a-box’ (NIAB) kit was used to provide human-relevant data on compound efficacy for INI-822.
Science Daily: Pharmacology News
DECEMBER 5, 2023
Researchers have developed a promising new solar-powered atmospheric water harvesting technology that could help provide enough drinking water for people to survive in difficult, dryland areas: They synthesized a super hygroscopic gel capable of absorbing and retaining an unparalleled amount of water. One kilogram of dry gel could adsorb 1.18 kilograms of water in arid atmospheric environments and up to 6.4 kilograms in humid atmospheric environments.
Drugs.com
DECEMBER 4, 2023
MONDAY, Dec. 4, 2023 -- Colon cancer survivors can give their health a boost by eating more navy beans, a new clinical trial finds.Small, white navy beans are full of gut-supporting fibers, amino acids and other nutrients that can help the.
BioPharma Drive: Drug Pricing
DECEMBER 8, 2023
The setbacks for Merck demonstrate the challenge drug developers face in improving on Keytruda, which has brought in at least $18 billion so far this year for its maker.
Drug Discovery World
DECEMBER 6, 2023
The UK government has published new terms for the Statutory Scheme for branded medicines, which controls the prices of medicines paid by the NHS. The announcement follows the agreement in mid-November of a new Voluntary Scheme for Pricing, Access and Growth (VPAG), a negotiated alternative scheme which companies can opt into over the Statutory Scheme.
Science Daily: Pharmacology News
DECEMBER 7, 2023
ChatGPT may do an impressive job at correctly answering complex questions, but a new study suggests it may be absurdly easy to convince the AI chatbot that it's in the wrong.
Drugs.com
DECEMBER 6, 2023
WEDNESDAY, Dec. 6, 2023 -- Neurologist Dr. Deborah Holder says she often has parents come to her with kids who've experienced what they call "funny spells." “Sometimes I start talking to a parent and find out the parent has [also] had.
BioPharma Drive: Drug Pricing
DECEMBER 6, 2023
The pharma is developing Fabhalta, now cleared for paroxysmal nocturnal hemoglobinuria, for several other rare, complement-driven diseases.
Drug Discovery World
DECEMBER 4, 2023
A novel DNA vaccine in combination with chemotherapy has demonstrated promising clinical results against a deadly form of ovarian cancer. The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In a new paper, a team of scientists from CureLab Oncology, the NN Alexandrov National Cancer Center and Minsk City Oncology Center have demonstrated a clear clinical benefit
Science Daily: Pharmacology News
DECEMBER 8, 2023
A landmark study has shown that severe asthma can be controlled using biologic therapies, without the addition of regular high-dose inhaled steroids which can have significant side effects.
Drugs.com
DECEMBER 5, 2023
TUESDAY, Dec. 5, 2023 -- People with epilepsy suffer quicker declines in thinking than people without the brain disorder, particularly if they also have risk factors like high blood pressure or diabetes, a new study finds.The difference was.
Broad Institute
DECEMBER 7, 2023
Approach studies how rare gene variant pairs contribute to disease By Tom Ulrich December 7, 2023 Breadcrumb Home Approach studies how rare gene variant pairs contribute to disease Strategy infers whether variants that appear in the same gene are on the same copy of that gene, could improve genetic diagnosis of disease By Tracy Hampton, Massachusetts General Hospital December 7, 2023 Credit: Susanna Hamilton, Broad Communications Related Programs Program in Medical and Population Genetics Relate
Drug Discovery World
DECEMBER 8, 2023
News round-up for 4-8 December by DDW Digital Content Editor Diana Spencer. The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a possibly game-changing schizophrenia drug entering human trials.
Science Daily: Pharmacology News
DECEMBER 5, 2023
A new report equips policymakers with the latest and most pivotal climate science research from the previous 18 months, synthesized to help inform negotiations at COP28 and policy implementation through 2024 and beyond.
Drug Target Review
DECEMBER 4, 2023
According to the Personalised Medicine Coalition , 34 percent of all new drugs approved by the US Food and Drug Administration (FDA) in 2022 are personalised medicines. What’s more, investment in this sector is predicted to rise by 70 percent by 2030. The reason for all this attention and investment is clear: significant benefits for patients. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, redu
Expert insights. Personalized for you.
300 
Let's personalize your content